Join        Login             Stock Quote

VERONA PHARMA PLC - Verona Pharma appoints new CEO

Tuesday, May 1, 2012 2:00 AM

                               Verona Pharma plc                               
                      ("Verona Pharma" or the "Company")                       
                        Verona Pharma appoints new CEO                         
  Appointment of experienced biotechnology CEO as part of succession planning  

1 May 2012 - London, UK - Verona Pharma plc (AIM: VRP.L), the Company focused on discovering and developing first-in-class drugs for respiratory disease, today announced the appointment of Dr Sven Jan-Anders Karlsson (aged 57)as Chief Executive Officer with effect from 1 June 2012.

Dr Karlsson has broad pharmaceutical and biotechnology R&D and corporate experience. He was formerly the CEO at S*BIO, a Singapore and US based biotechnology company focused on the discovery and development of novel small molecule anti-cancer drugs. Before S*BIO, Dr Karlsson was Executive Vice President of Pharma Global Research at Bayer Healthcare after holding senior leadership positions at Rhone-Poulenc Rorer (now Sanofi) and Astra (now AstraZeneca).

The current CEO, Michael Walker, was one of the co-founders of Verona Pharma. Under his leadership the Company acquired and rapidly progressed two novel drug candidates through five successful Phase II clinical trials. Michael will work closely with Jan-Anders to ensure a successful handover of the CEO position and will continue to serve the Company as a Senior Scientific Advisor to the Board.

Professor Clive Page, Chairman of Verona Pharma, said:"Michael and I have worked together on various projects for many years including the founding of Verona Pharma. Michael has brought considerable scientific and commercial experience to the Company and we are delighted that he will continue to contribute as a scientific advisor following the appointment of Dr Karlsson."

"We have taken time to identify and recruit the right person to take over from Michael after he had notified the Board of his intention to step down. We believe Jan-Anders' experience in the pharmaceutical and biotechnology sector will be invaluable to Verona Pharma as we move our clinical programs forward, and continue to grow and expand the Company. We very much look forward to working with him."

Dr Karlsson said: "Verona Pharma is developing drugs for patients with respiratory diseases where the medicines are either inadequate or failing to meet patients' needs.


Fundamental data is provided by Zacks Investment Research, and Commentary, news and Press Releases provided by YellowBrix and Quotemedia.
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.